U.S. markets close in 3 hours 42 minutes
  • S&P 500

    3,469.01
    -14.80 (-0.42%)
     
  • Dow 30

    28,515.80
    -90.51 (-0.32%)
     
  • Nasdaq

    11,625.99
    -45.57 (-0.39%)
     
  • Russell 2000

    1,639.01
    +5.20 (+0.32%)
     
  • Crude Oil

    41.04
    +0.16 (+0.39%)
     
  • Gold

    1,911.90
    +5.50 (+0.29%)
     
  • Silver

    24.74
    +0.33 (+1.35%)
     
  • EUR/USD

    1.1786
    +0.0058 (+0.49%)
     
  • 10-Yr Bond

    0.7620
    +0.0180 (+2.42%)
     
  • GBP/USD

    1.2998
    +0.0090 (+0.70%)
     
  • USD/JPY

    105.4100
    +0.0160 (+0.02%)
     
  • BTC-USD

    11,766.56
    +709.55 (+6.42%)
     
  • CMC Crypto 200

    240.01
    +6.34 (+2.71%)
     
  • FTSE 100

    5,884.65
    -34.93 (-0.59%)
     
  • Nikkei 225

    23,671.13
    +260.50 (+1.11%)
     

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020

CANTON, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2020 financial results will be reported after the market closes on Monday, August 10.

Management will host a conference call at 5:00 p.m. Eastern Time on August 10 to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 4153175. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 4153175. The webcast will be archived at investors.organogenesis.com.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.


Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500

Press and Media Inquiries:
Organogenesis
Marcus Girolamo
MGirolamo@organo.com
817-688-4767